Exploring the Use of Diabetic Medications for Non-Diabetic Conditions: A Comprehensive Literature Review
暂无分享,去创建一个
O. E. Okobi | Rosemary O. Iriowen | Temituoyo F. Edema | Victor O. Dike | Taiwo I. Ogundipe | Ifeoluwa O. Oluwatowoju | Bright C. Nwatamole | Ogochukwu A. Okonkwo | O. Okobi
[1] Lawrence A Leiter,et al. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF. , 2023, JACC. Heart failure.
[2] S. Hadjadj,et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo. , 2023, Kidney international.
[3] Akshay S. Desai,et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials , 2022, The Lancet.
[4] Lawrence A Leiter,et al. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. , 2022, The Canadian journal of cardiology.
[5] T. Stürmer,et al. Antihyperglycemic Medication Use Among U.S. Adults With Hemodialysis-Dependent Kidney Disease and Comorbid Diabetes. , 2022, Diabetes care.
[6] G. Filippatos,et al. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes , 2022, Circulation.
[7] D. Cherney,et al. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations , 2022, Kidney international reports.
[8] National Kidney Foundation 2022 Spring Clinical Meeting Abstracts , 2022, American Journal of Kidney Diseases.
[9] D. Lee,et al. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions , 2022, Kidney research and clinical practice.
[10] S. Verma,et al. Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis , 2022, ESC heart failure.
[11] Sanjiv J. Shah,et al. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial , 2021, Circulation.
[12] J. McMurray,et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. , 2021, The lancet. Diabetes & endocrinology.
[13] Deepak L. Bhatt,et al. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure , 2021, Annals of Internal Medicine.
[14] C. L. le Roux,et al. Clinical Impact of Liraglutide as a Treatment of Obesity , 2021, Clinical pharmacology : advances and applications.
[15] Lawrence A Leiter,et al. Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. , 2021, Canadian journal of diabetes.
[16] J. Butler,et al. Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. , 2021, Circulation.
[17] G. Filippatos,et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis , 2020, ESC heart failure.
[18] J. McMurray,et al. Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.
[19] G. Fonarow,et al. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. , 2020, Circulation.
[20] Sandeep R. Das,et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2020, Journal of the American College of Cardiology.
[21] M. Vaduganathan,et al. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. , 2020, JAMA cardiology.
[22] S. Verma,et al. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors , 2020, JACC. Basic to translational science.
[23] J. Newman,et al. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. , 2020, Journal of the American College of Cardiology.
[24] Kamlesh Khunti,et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. , 2020, The lancet. Diabetes & endocrinology.
[25] F. Rutters,et al. Risk and management of pre-diabetes , 2019, European journal of preventive cardiology.
[26] S. Selph,et al. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review , 2019, Systematic Reviews.
[27] J. McMurray,et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.
[28] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[29] N. Brown,et al. Sitagliptin decreases visceral fat and blood glucoses in women with polycystic ovarian syndrome. , 2019, The Journal of clinical endocrinology and metabolism.
[30] W. E. Sanabria,et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. , 2019, Lancet.
[31] K. Tuttle,et al. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7) , 2019, Diabetes, obesity & metabolism.
[32] Flávia R. Oliveira,et al. Recent advances in the understanding and management of polycystic ovary syndrome , 2019, F1000Research.
[33] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[34] Z. Younossi. Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.
[35] Deepak L. Bhatt,et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. , 2019, Circulation.
[36] A. Avogaro,et al. Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes , 2018, The Journal of clinical endocrinology and metabolism.
[37] K. Tuttle,et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. , 2018, The lancet. Diabetes & endocrinology.
[38] S. Lippmann,et al. Risks vs Benefits for SGLT2 Inhibitor Medications. , 2018, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.
[39] M. Treppendahl,et al. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial , 2018, Diabetes & vascular disease research.
[40] Y. Birnbaum,et al. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials , 2018, Cardiovascular Drugs and Therapy.
[41] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[42] Neha J. Pagidipati,et al. Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.
[43] E. Wittbrodt,et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research , 2017, Diabetes, metabolic syndrome and obesity : targets and therapy.
[44] Merlin C. Thomas,et al. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. , 2017, Diabetes & metabolism.
[45] V. Vallon,et al. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.
[46] A. Mehta,et al. Liraglutide for weight management: a critical review of the evidence , 2016, Obesity science & practice.
[47] W. Cefalu,et al. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus , 2016, Current opinion in endocrinology, diabetes, and obesity.
[48] N. Nader,et al. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries , 2016, Archives of Gynecology and Obstetrics.
[49] M. Nauck,et al. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors , 2016, Diabetes, obesity & metabolism.
[50] A. Astrup,et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.
[51] S. Geerlings,et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. , 2014, Diabetes research and clinical practice.
[52] J. Nestler,et al. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. , 2010, Fertility and sterility.
[53] N. Mikhail. Cardiovascular Effects of Liraglutide. , 2019, Current hypertension reviews.
[54] H. Teede,et al. Polycystic ovary syndrome , 2016, Nature Reviews Disease Primers.
[55] R. Barnes. Polycystic ovarian disease. , 1997, Current therapy in endocrinology and metabolism.